Susanna Gatti High

US·SEC (Form 4)

Dyne Therapeutics, Inc.

Cumul. flow

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (53 ops.)

€12.1M

Latest filing published 19 Sept 2024 for Dyne Therapeutics, Inc., €134k.

Filing timeline

BuySale

Susanna Gatti High

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Susanna Gatti High: trading record in brief

Susanna Gatti High is a declared insider at 2 companies; the most frequent names are Dyne Therapeutics, Inc. and bluebird bio, Inc. In total, 72 filings cover trades dated from 1 December 2016 to 18 September 2024.

The open-market record consists of 53 sales worth €12.1M, with no purchase. Besides market trades, the filings include 6 share grants and 10 option exercises. Since January 2024: no purchases and 21 sales on the market.

On 19 September 2024 came the latest disclosure, an open-market sale for €144k in Dyne Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.

Companies and markets linked to Susanna Gatti High

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Dyne Therapeutics, Inc. (US)

Declarations24 total

▼
Susanna Gatti High
Chief Operating OfficerExecutives18 Sept 2024Dyne Therapeutics, Inc.
149,339 USD37SEC
4,340 shares@ US$34.415.9% of flowCommon StockSEC:0000950170-24-108154:0
▼
Susanna Gatti High
Chief Operating OfficerExecutives11 Sept 2024Dyne Therapeutics, Inc.
81,256 USD36SEC
2,548 shares@ US$31.893.2% of flowCommon StockSEC:0000950170-24-105512:0
▼
Susanna Gatti High
Chief Operating OfficerExecutives19 Aug 2024Dyne Therapeutics, Inc.
116,216 USD36SEC
2,582 shares@ US$45.014.6% of flowCommon StockSEC:0000950170-24-099124:0
◇
Susanna Gatti High
Chief Operating OfficerExecutives21 Jun 2024Dyne Therapeutics, Inc.
165,020 USD0SEC
29,787 shares@ US$5.546.8% of flowCommon StockSEC:0000950170-24-081748:0
◇
Susanna Gatti High
Chief Operating OfficerExecutives21 Jun 2024Dyne Therapeutics, Inc.
165,020 USD19SEC
29,787 shares@ US$5.546.8% of flowCommon StockSEC:0000950170-24-077029:0
◇
Susanna Gatti High
Chief Operating OfficerExecutives12 Jun 2024Dyne Therapeutics, Inc.
221,600 USD19SEC
40,000 shares@ US$5.549.0% of flowCommon StockSEC:0000950170-24-073289:0
◇
Susanna Gatti High
Chief Operating OfficerExecutives10 Jun 2024Dyne Therapeutics, Inc.
443,200 USD20SEC
80,000 shares@ US$5.5418.0% of flowCommon StockSEC:0000950170-24-072153:0
▼
Susanna Gatti High
Chief Operating OfficerExecutives16 May 2024Dyne Therapeutics, Inc.
63,422 USD36SEC
2,249 shares@ US$28.202.6% of flowCommon StockSEC:0000950170-24-062078:0
▼
Susanna Gatti High
Chief Operating OfficerExecutives8 Mar 2024Dyne Therapeutics, Inc.
717,367 USD39SEC
26,908 shares@ US$26.6628.7% of flowCommon StockSEC:0000950170-24-030485:0
▼
Susanna Gatti High
Chief Operating OfficerExecutives7 Mar 2024Dyne Therapeutics, Inc.
41,127 USD36SEC
1,591 shares@ US$25.851.7% of flowCommon StockSEC:0000950170-24-029614:0
▼
Susanna Gatti High
Chief Operating OfficerExecutives11 Dec 2023Dyne Therapeutics, Inc.
17,324 USD36SEC
1,616 shares@ US$10.720.7% of flowCommon StockSEC:0001209191-23-058329:0
◆
Susanna Gatti High
Chief Operating OfficerExecutives15 Nov 2023Dyne Therapeutics, Inc.
0SEC
94,893 shares0Common StockSEC:0001209191-23-055526:0
▼
Susanna Gatti High
Chief Operating OfficerExecutives2 Nov 2023Dyne Therapeutics, Inc.
73,549 USD18SEC
9,939 shares@ US$7.403.0% of flowCommon StockSEC:0001209191-23-054194:0
▼
Susanna Gatti High
Chief Operating OfficerExecutives18 Sept 2023Dyne Therapeutics, Inc.
25,144 USD37SEC
2,672 shares@ US$9.418.5% of flowCommon StockSEC:0001209191-23-050172:0
▼
Susanna Gatti High
Chief Operating OfficerExecutives12 Sept 2023Dyne Therapeutics, Inc.
17,020 USD36SEC
1,635 shares@ US$10.410.7% of flowCommon StockSEC:0001209191-23-049359:0
▼
Susanna Gatti High
Chief Operating OfficerExecutives13 Jun 2023Dyne Therapeutics, Inc.
20,199 USD36SEC
1,625 shares@ US$12.430.8% of flowCommon StockSEC:0001209191-23-037166:0
▼
Susanna Gatti High
Chief Operating OfficerExecutives14 Mar 2023Dyne Therapeutics, Inc.
20,781 USD36SEC
1,559 shares@ US$13.330.8% of flowCommon StockSEC:0001209191-23-018980:0
◆
Susanna Gatti High
Chief Operating OfficerExecutives9 Dec 2022Dyne Therapeutics, Inc.
0SEC
44,000 shares0Common StockSEC:0001209191-22-060970:0
●
Susanna Gatti High
Chief Operating OfficerExecutives20 Sept 2022Dyne Therapeutics, Inc.
36,017 USD18SEC
2,629 shares@ US$13.701.6% of flowCommon StockSEC:0001209191-22-050888:0
●
Susanna Gatti High
Chief Operating OfficerExecutives15 Sept 2022Dyne Therapeutics, Inc.
11,043 USD18SEC
786 shares@ US$14.050.5% of flowCommon StockSEC:0001209191-22-050120:0
●
Susanna Gatti High
Chief Operating OfficerExecutives14 Jun 2022Dyne Therapeutics, Inc.
3,970 USD11SEC
802 shares@ US$4.950.2% of flowCommon StockSEC:0001209191-22-037146:0
▼
Susanna Gatti High
Chief Operating OfficerExecutives11 Mar 2022Dyne Therapeutics, Inc.
6,678 USD29SEC
765 shares@ US$8.730.3% of flowCommon StockSEC:0001209191-22-018535:0
◆
Susanna Gatti High
Chief Operating OfficerExecutives10 Dec 2021Dyne Therapeutics, Inc.
0SEC
40,315 shares0Common StockSEC:0001209191-21-069423:0
▼
Susanna Gatti High
Chief Operating OfficerExecutives23 Sept 2021Dyne Therapeutics, Inc.
42,206 USD29SEC
2,451 shares@ US$17.221.7% of flowCommon StockSEC:0001209191-21-057527:0

24 of 24 declarations

Susanna Gatti High

Insider track record

Susanna Gatti High: trading record in brief

Companies and markets linked to Susanna Gatti High

Similar companies

Related executives